Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Canaccord Fireside Chat & pelareorep's approval in mBC

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Aug 14, 2023 5:06am

153 Views

Post# 35586476

RE:RE:RE:RE:RE:RE:RE:RE:Canaccord Fireside Chat & pelareorep's approval in mBC

No, Matt has stated before that for mBC they would be following a traditional approval route. ONCY to the best of my knowledge has NEVER mentioned accelerated approval...

Thinking this to be the case is hopium... The two Phase IIIs look set to follow the traditional path, treat, analyse, submit...

Unless of course, they can correclate their biomarker(s) to a surrogate end point, but I don't think Bracelet-1 would have enough statisitcal power to show that, and certainly not the Panc trial.

Sorry to burst yet another bubble.

<< Previous

Bullboard Posts

Next >>

Three mispriced stocks exposed to major market tailwinds